The most recent developments in the field of A-to-I RNA modification, with a special emphasis on the roles of A-to-I in the genesis and progression of cancer. Adenosine-to-inosine (A-to-I) RNA editing ...

In a recent study in Nature Communications, researchers examined the adenosine-to-inosine (A-to-I) nucleoside editing of postmortem and live prefrontal cortical tissues. Researchers found that RNA ...

On October 16, a biotechnology company in Massachusetts in the U.S. named Wave Life Sciences made headlines for becoming the first company to treat a genetic condition by editing RNA at the clinical ...

Genetic editing holds promise to treat incurable diseases, but the most popular method — CRISPR — sometimes does more harm than good. A new study from University of California San Diego and Yale ...

Despite remarkable advancements, such as Wave Life Sciences pioneering the first clinical candidate and significant investments like Ascidian Therapeutics securing $40 million for their RNA editing ...

All starting from the same DNA, neurons ultimately take on individual characteristics in the brain and body. Differences in which genes they transcribe into RNA help determine which type of neuron ...

ProQR Therapeutics is advancing its Axiomer ADAR-mediated RNA editing pipeline, aiming to file a Clinical Trial Application for its lead program AX-0810, targeting NTCP for cholestatic diseases, by Q2 ...

ゲノムは、自身が持っている遺伝子の発現を調節する方法を多数作り出してきた。今回、新しい発現調節機構がD Spectorらによって発見され、Cellに報告されている。彼らは、普段は核内に保留されているが、ストレスに応じて切断され、翻訳可能なmRNAとして ...

Many foundational research technologies have transformed cellular therapies, moving treatments from concept to clinic. In the past decade, chimeric antigen receptors (CAR) and genome editing are two ...